NCT03184480 - Arnuity® Ellipta® Drug Use Investigation | Biotech Hunter

Enrollment

336

Participants

Timeline

Start Date

August 19, 2017

Primary Completion Date

March 17, 2021

Study Completion Date

March 17, 2021

Conditions

Asthma

Interventions

DRUG

Arnuity Ellipta

The active component of Arnuity Ellipta is fluticasone furoate and it is indicated for the treatment of bronchial asthma. Post-marketing investigation of ARNUITY ELLIPTA will be carried out in this analysis.

Trial Locations (2)

050-0074

GSK Investigational Site, Hokkaido

852-8105

GSK Investigational Site, Nagasaki